Premium
Phase II Study of Megestrol Acetate for Metastatic Carcinoma of the Prostate
Author(s) -
CROMBIE CATHERINE,
RAGHAVAN D.,
PAGE J.,
WOODS R.,
DALLEY D.,
DEVINE RHONDA,
ROSEN M.
Publication year - 1987
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1987.tb04843.x
Subject(s) - megestrol acetate , prostate carcinoma , medicine , megestrol , prostate , oncology , metastatic carcinoma , carcinoma , cancer
Summary— Forty‐three males with recurrent and metastatic cancer of the prostate were treated with megestrol acetate (160 mg/day orally) after having failed first‐line hormonal treatment (orchiectomy or diethylstilboestrol). Thirty‐seven patients were evaluated objectively for response, 28 of whom received the drug for more than 6 weeks. One patient had a partial response (National Prostatic Cancer Project criteria) and seven had stable disease. Toxicity was usually mild, although five patients developed a transient rise in liver enzymes and one patient had a grand mal fit. Three patients showed evidence of tumour “flare”. Megestrol acetate has only limited efficacy in patients previously treated for prostatic cancer by hormonal manipulation.